2-(4-溴苯基)-3-甲基丁酸甲酯 | 1061284-70-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4-溴苯基)-3-甲基丁酸甲酯
• 英文名称: methyl 2-(4-bromophenyl)-3-methylbutanoate
• 英文别名: 2-(4-bromophenyl)-3-methylbutyric acid methyl ester
• CAS: 1061284-70-5
• 化学式: C₁₂H₁₅BrO₂
• 分子量: 271.154
• InChiKey: YRCKHQQSBKSPKO-UHFFFAOYSA-N

物化性质

• 沸点：
  307.2±17.0 °C(Predicted)
• 密度：
  1.296±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-(4-溴苯基)-3-甲基丁酸甲酯 在 18-冠醚-6 、 potassium tert-butylate 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 25.0h， 生成 C₁₅H₁₉BrO₄
  参考文献：
  名称：

  Successful reduction of off-target hERG toxicity by structural modification of a T-type calcium channel blocker

  摘要：

  To obtain an optimized T-type calcium channel blocker with reduced off-target hERG toxicity, we modified the structure of the original compound by introducing a zwitterion and reducing the basicity of the nitrogen. Among the structurally modified compounds we designed, compounds 5 and 6, which incorporate amides in place of the original compound's amines, most appreciably alleviated hERG toxicity while maintaining T-type calcium channel blocking activity. Notably, the benzimidazole amide 5 selectively blocked T-type calcium channels without inhibiting hERG (hERG/T-type >= 220) and L-type channels (L-type/T-type = 96), and exhibited an excellent pharmacokinetic profile in rats. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.078
• 作为产物：
  描述：

  对溴苯乙酸 在 氯化亚砜 、 potassium tert-butylate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-(4-溴苯基)-3-甲基丁酸甲酯
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRIMIDINES
  [FR] PYRIMIDINES SUBSTITUÉES

  摘要：

  本发明涉及作为HIF脯氨酰羟化酶抑制剂用于治疗贫血和类似病症的取代嘧啶。

  公开号：

  WO2013043624A1
• 作为试剂：
  描述：

  4-溴苯乙酸甲酯 、 、 potassium tert-butylate 、 2-碘代丙烷 、 在 氮 、 乙酸乙酯 、 Brine 、 Sodium sulfate-III 、 crude product 、 2-(4-溴苯基)-3-甲基丁酸甲酯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.5h， 以to afford the title compound, 13-b, (1.3 g, 48%)的产率得到2-(4-溴苯基)-3-甲基丁酸甲酯
  参考文献：
  名称：

  SUBSTITUTED PYRIMIDINES

  摘要：

  本发明涉及替代嘧啶类化合物，用于治疗贫血和类似疾病的HIF脯氨酸羟化酶抑制剂。

  公开号：

  US20140349972A1

文献信息

• NOVEL PHENYLACETATE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF AND COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASES INDUCED BY ACTIVATION OF T-TYPE CALCIUM ION CHANNEL CONTAINING THE SAME AS AN ACTIVE INGREDIENT
  申请人：SHIN Kye Jung

  公开号：US20100056545A1

  公开（公告）日：2010-03-04

  Disclosed herein are a new phenylacetate derivative represented by Chemical Formula 1 or pharmaceutically acceptable salt thereof, a preparation method thereof, and a composition for prevention or treatment of diseases induced by the activation of T-type calcium ion channels containing the same. The composition containing the phenylacetate derivative according to the present invention effectively inhibits the activation of T-type calcium ion channels and may be useful in the prevention or treatment of diseases such as hypertension, cancer, epilepsy, and neurogenic pains induced by the activation of T-type calcium ion channels. wherein, X, R 1 , and R 3 are as defined herein.

  本公开揭示了一种由化学式1表示的新苯乙酸盐衍生物或其药用可接受的盐，其制备方法以及含有该衍生物的预防或治疗由T型钙离子通道激活引起的疾病的组合物。根据本发明的含有苯乙酸盐衍生物的组合物有效抑制T型钙离子通道的激活，并可能在预防或治疗高血压、癌症、癫痫和由T型钙离子通道激活引起的神经痛等疾病中发挥作用。其中，X，R1和R3如本文所定义。
• Phenylacetate derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and composition for prevention or treatment of diseases induced by activation of T-type calcium ion channel containing the same as an active ingredient
  申请人：Korea Institute of Science and Technology

  公开号：US07939672B2

  公开（公告）日：2011-05-10

  Disclosed herein are a new phenylacetate derivative represented by Chemical Formula 1 or pharmaceutically acceptable salt thereof, a preparation method thereof, and a composition for prevention or treatment of diseases induced by the activation of T-type calcium ion channels containing the same. The composition containing the phenylacetate derivative according to the present invention effectively inhibits the activation of T-type calcium ion channels and may be useful in the prevention or treatment of diseases such as hypertension, cancer, epilepsy, and neurogenic pains induced by the activation of T-type calcium ion channels. wherein, X, R1, and R3 are as defined herein.

  本文披露了一种新的苯乙酸衍生物，其化学式为1，或其药学上可接受的盐，以及其制备方法和包含该衍生物的预防或治疗由T型钙离子通道激活引起的疾病的组合物。本发明所述的含有苯乙酸衍生物的组合物有效地抑制了T型钙离子通道的激活，可能有助于预防或治疗高血压、癌症、癫痫和由T型钙离子通道激活引起的神经性疼痛等疾病。其中，X、R1和R3如本文所定义。
• Substituted pyrimidines
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US09079930B2

  公开（公告）日：2015-07-14

  The present invention relates to substituted pyrimidines useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

  本发明涉及替代嘧啶类化合物，可作为HIF脯氨酸羟化酶抑制剂用于治疗贫血和类似疾病。
• Synthesis and evaluation of α,α′-disubstituted phenylacetate derivatives for T-type calcium channel blockers
  作者：Hyung Kook Lee、Yun Suk Lee、Eun Joo Roh、Hyewhon Rhim、Jae Yeol Lee、Kye Jung Shin

  DOI：10.1016/j.bmcl.2008.06.037

  日期：2008.8

  We have synthesized and evaluated alpha,alpha'-disubstituted phenylacetate derivatives that were designed as T-type calcium channel blockers. Among them, compound 10e (IC50 = 8.17 +/- 0.48 nM) showed the most potent T-type calcium current blocking activity and higher potency than Mibefradil (IC50 = 1.34 +/- 0.49 mu M). The PK profile and subtype selectivity over L-type calcium channel were satisfied for further animal assay using disease model. (c) 2008 Elsevier Ltd. All rights reserved.
• US7939672B2
  申请人：——

  公开号：US7939672B2

  公开（公告）日：2011-05-10